Thiogamma

Quick links to important sections

Thiogamma

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thiogamma

What is Thiogamma? Definition and Classification

Property Description
Active ingredient Thioctic acid (Alpha-lipoic acid)
Forms Infusion solution, Film-coated tablets
Pharmacological class Metabolic agent, Endogenous antioxidant
Common use Supports nerve function in polyneuropathy
Origin Naturally occurring, but produced synthetically as a racemate

Thiogamma is a pharmaceutical preparation whose single active component is Thioctic acid, also formally known as alpha-Lipoic acid. This substance is scientifically classified as both a metabolic agent and an endogenous antioxidant. This classification indicates that the compound works within the body to counter damaging processes, similar to naturally occurring protective substances. The drug is considered a vitamin-like substance essential for supporting cellular energy and combating damage from highly reactive molecules, particularly in tissues susceptible to oxidative stress.


Thioctic Acid: Composition, Origin, and Available Forms

The active ingredient, Thioctic acid, is a compound critical for mitochondrial enzyme complexes, such as the pyruvate dehydrogenase complex, in the body's energy metabolism. While this compound is naturally present, the substance in Thiogamma is produced synthetically for pharmaceutical use, typically as a racemate—a mixture containing both the physiologically active R-enantiomer and the S-enantiomer. This compound is recognized for its free radical scavenging activity. Thiogamma is differentiated by its available pharmaceutical preparations, which include a ready-to-use concentrate for infusion solution (often packaged as the Thiogamma Turbo-Set) intended for intravenous delivery, and film-coated tablets for oral use.


General Purpose and Physiological Rationale

The overall purpose of Thiogamma is to support cellular health, especially in nerve tissue, by mitigating the effects of oxidative stress and facilitating key metabolic processes. As a lipid- and water-soluble antioxidant, Thioctic acid also aids in the regeneration of endogenous antioxidants like Glutathione. This dual regenerative and protective mechanism helps support the proper function of structures, such as the peripheral nerves, offering a therapeutic rationale in the context of nerve damage.

Regulatory References

  1. FDA UNII: ALPHA LIPOIC ACID
  2. NCBI/NIH: Alpha-Lipoic Acid (StatPearls)

What side effects are possible with Thiogamma?

Possible Side Effects and Safety Information

Thiogamma (thioctic acid) is associated with officially documented adverse effects, categorized according to their frequency and the system-organ class they affect. The majority of reactions are documented as Very Rare (may affect up to 1 in 10,000 people) or of Frequency Unknown (cannot be estimated from available data) in regulatory documents.


Documented Adverse Reactions by System

  • Immune System Disorders: Include allergic skin reactions (such as urticaria, itching, and rash) and systemic allergic reactions, which may, in rare cases, lead to anaphylactic shock.
  • Metabolism and Nutrition Disorders: Hypoglycaemia-like symptoms (e.g., dizziness, sweating, and headaches) have been reported due to the drug’s potential to enhance glucose utilization.
  • Gastrointestinal and Nervous System: Very rare adverse reactions include nausea, vomiting, stomach pain, diarrhea, and a change in the sense of taste (dysgeusia).

Serious Reactions and Specific Safety Notes

Among the serious adverse reactions documented is Insulin Autoimmune Syndrome (IAS), an event of unknown frequency linked to disturbances in glucose regulation. Regulatory information notes that individuals with a specific human leukocyte antigen (HLA) genotype are considered more susceptible to developing IAS.

For diabetic patients, the enhanced glucose utilization means they must be mindful of the potential for hypoglycaemia-like symptoms. Safety data also cautions against use in cases of known hypersensitivity to the active substance. Furthermore, official documents note that effects such as a sensation of pressure in the head and respiratory distress may occur following rapid intravenous infusion.

Overdose and Emergency Response

Overdose with Thioctic acid is a serious condition that requires immediate medical intervention based on official regulatory information. Initial manifestations of overdose may include non-specific symptoms such as nausea, vomiting, and headache.

Severe Manifestations and Life-Threatening Risks

Significant overdose is documented to present with severe neurological effects, including seizures and loss of consciousness. Due to the substance's metabolic activity, signs of hypoglycemia (dizziness, sweating, impaired vision) may also occur. Severe intoxication has been associated with lethal outcome in some cases.

Documented systemic complications include conditions such as lactic acidosis, serious disturbances of blood clotting (coagulopathy), shock, rhabdomyolysis (muscle damage), and multiple organ dysfunction. The risk of these severe outcomes is notably increased when the dosage exceeds 10 grams of Thioctic acid and is used in conjunction with alcohol.

Emergency Response Mandate

If there is any suspicion of a significant overdose with Thioctic acid, regulatory guidance mandates that the person must go prompt and seek transportation to the hospital. Treatment for severe poisoning is required in a hospital setting and is managed according to the general treatment principles for cases of poisoning, as no specific antidote is known for Thioctic acid.

Therapeutic Uses of Thiogamma

What Thiogamma Treats: Main Uses and Benefits

Thiogamma is commonly used in clinical settings for the management of symptomatic diabetic polyneuropathy, a condition involving peripheral nerve damage associated with chronic diabetes. The treatment is considered relevant for symptomatic support to address the disruptive manifestations resulting from this underlying nerve condition.

Alleviating Neuropathic Pain and Sensory Disturbances

The medication is specifically applied to ease a cluster of challenging sensory manifestations, including severe burning sensations, intense lancinating pain, and abnormal feelings like tingling and numbness (paresthesia). It is relevant for managing symptoms that interfere with daily comfort. By helping to manage the intensity of established symptoms, it may support the patient during difficult episodes by easing distress.

Supporting Comfort in Chronic Nerve Conditions

Thiogamma is generally utilized as part of a long-term therapeutic strategy when peripheral nerve symptoms create noticeable interference with daily activities. Applied across domains where additional symptomatic support is needed, this therapy contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.


Quick Fact: Relief for Neuropathic Symptoms

The medication is commonly used to help with symptoms related to physical discomfort and heightened physiological activity in conditions characterized by periods of heightened symptoms and fluctuating manifestations.

Regulatory References

  1. Alpha-Lipoic Acid - StatPearls - NCBI Bookshelf

Eligibility and Restrictions for Use

Thiogamma (thioctic acid/alpha-lipoic acid) is an adult-focused medication with strict eligibility rules established by regulatory bodies.

Contraindications and Exclusions

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity or allergy to alpha-lipoic acid or any of the product's components.
Age Exclusion Children and Adolescents (under 18 years); use is not recommended due to a lack of clinical experience and established safety data in this age group.

Conditional Use and Restrictions

Use of Thiogamma is conditional or requires special monitoring in several adult populations:

  • Pregnancy and Lactation: Use is not recommended unless a physician determines the potential benefits strictly outweigh the unknown risks. Adequate human studies are lacking, and fetal risk cannot be entirely ruled out.
  • Diabetes Mellitus: Requires close monitoring of blood glucose levels and possible adjustment of antidiabetic medication to mitigate the risk of hypoglycemia (low blood sugar).
  • Thiamine Deficiency: Patients, particularly those with a history of chronic heavy alcohol use, must receive adequate Thiamine (Vitamin B1) supplementation prior to and during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details documented interactions with other medicines and substances as specified in official regulatory labeling.


Documented Interactions

Co-administration of the active substance in Thiogamma (thioctic acid) with certain other medicines or products can lead to changes in drug effectiveness or absorption. These interactions are categorized as follows:

  • Anti-Diabetic Medicines: Thioctic acid can reinforce the blood-sugar-lowering effect of insulin and oral anti-diabetics. This pharmacodynamic interaction requires close monitoring of blood sugar levels, especially when treatment is first initiated. Dose adjustments to the anti-diabetic medicine may be necessary to prevent hypoglycemia.

  • Metal-Containing Preparations: Medicines and supplements containing metal compounds, such as those with iron or magnesium, can bind to thioctic acid. This binding reduces the absorption and subsequent efficacy of Thiogamma. To avoid this reduced absorption, a sufficient time interval must be maintained between the intake of Thiogamma and the metal-containing preparation.

  • Cisplatin: The active substance may decrease the cytotoxic effect of the anti-cancer medicine cisplatin.

  • Alcohol: Consumption of alcohol is strongly discouraged for patients with diabetic polyneuropathy, as it is a significant risk factor that can impair treatment success and worsen neuropathic symptoms. Oral administration of Thiogamma should be taken on an empty stomach, as food intake may hinder absorption.

Mechanism of Action

Thiogamma contains alpha-lipoic acid (ALA), an organosulfur compound that is easily absorbed and distributed across cellular membranes and the blood-brain barrier. The mechanism of action is primarily centered on its redox properties and its role as a key metabolic cofactor.

ALA's biological target is its function as a coenzyme in essential mitochondrial enzyme complexes, particularly the pyruvate dehydrogenase complex (PDC) and the alpha-ketoglutarate dehydrogenase complex (KDC). By acting as a co-factor, ALA facilitates the oxidative decarboxylation of alpha-keto acids, which are crucial steps in glucose metabolism and energy production via the citric acid cycle.

The compound also participates in an intracellular redox cycle with its reduced form, dihydrolipoic acid (DHLA). This pair directly scavenges reactive oxygen species (ROS) and reactive nitrogen species across both aqueous and lipid environments within the cell. Furthermore, DHLA indirectly modulates the cellular antioxidant network by regenerating the reduced forms of other endogenous antioxidants, including glutathione, Vitamin C, and Vitamin E.

This cascade of enhanced metabolic flux and reduced oxidative load results in a system-level physiological consequence of modulating the cellular redox status and supporting neuronal energy supply and signaling.

Dosage and Administration Information

The use of Thiogamma (thioctic acid) follows a standardized two-phase protocol that defines the administration method and schedule.

Administration Route and Dose Regimen

The treatment protocol begins with an initial intensive phase using the intravenous (IV) route. The dose for this period is 600 mg of alpha-lipoic acid, administered once daily. This IV phase typically spans 2 to 4 weeks. Following the initial course, a transition is made to the oral route using film-coated tablets for long-term continuation therapy. The standard maintenance dose is 600 mg, taken once daily.

Administration Specifics and Timing

Oral tablets must be swallowed whole with sufficient fluid and taken 30 minutes before the first meal of the day, specifically on an empty stomach. For the intravenous solution, administration requires the dose to be infused slowly over a duration of at least 30 minutes. The IV solution requires special handling as it must be protected from light during administration.

Use in Specific Populations

The use of thioctic acid is not recommended for children and adolescents under 18 years of age, primarily due to insufficient clinical experience in this population. If a patient misses a scheduled oral dose, the standard approach is to proceed with the next scheduled dose and not to double the dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of studies for Thiogamma

This section provides an overview of the clinical research conducted on Thioctic acid (the active ingredient in Thiogamma), focusing on the types of studies available and what outcomes the researchers monitored. This is a descriptive summary of the evidence landscape and is not clinical guidance.


Evidence for use in Symptomatic Diabetic Polyneuropathy (DSPN)

The primary research for Thioctic acid was studied for symptomatic Diabetic Polyneuropathy (DSPN), a condition where nerve damage causes discomfort, often in the feet and legs. The research base is primarily composed of Randomized Controlled Trials (RCTs) and subsequent systematic reviews that combine the findings of multiple trials. These studies were designed to evaluate patterns of change in patients experiencing specific nerve-related manifestations.

These research programs, including the ALADIN and SYDNEY series of trials, examined adult populations with diabetes and existing symptoms of nerve damage. The study designs often included a control group (such as a placebo) against which outcomes were observed. The studies monitored patient-reported outcomes describing perceived discomfort in research exploring short-term symptom changes over defined time intervals. The evidence contributes to understanding symptom patterns, particularly focusing on the intensity and variability of challenging sensations like pain and burning.

Research Focus: Assessing Sensory Symptoms

The short-term studies, often lasting around three weeks and involving intravenous administration, used specific standardized methods to track patient-reported outcomes. Researchers measured changes using the Total Symptom Score (TSS), which is used in research exploring how symptoms change over time. These outcomes relate to physical discomfort, covering specific manifestations such as lancinating pain, numbness, and tingling. Findings from these initial trials described patterns observed in the studies related to changes measured during the study period.

Studies conducted with oral administration over intermediate periods (up to six months) also monitored outcomes related to physical discomfort. Research monitored how outcomes related to physical discomfort changed in these observed populations over longer defined time intervals. However, the reported changes measured during the study period were observed to be less consistently reported across all oral trials when compared to the short-term intravenous research.


Study Duration: Short-Term Relief vs. Long-Term Follow-up

The available research provides two distinct scenarios for observation. The first scenario involves studies conducted during periods of increased symptom activity, typically over 3 to 4 weeks, to examine short-term symptom changes, primarily after intravenous therapy. These studies provided insight into short-term changes in outcomes reflecting daily functioning or activity level.

The second scenario involves research designed to examine potential effects over extended periods. One notable long-term study, lasting up to 4 years, focused on patients with mild-to-moderate DSPN. The long-term research was not primarily focused on symptom relief but was evaluated in studies examining patient-reported experiences and changes in physical function and nerve impairment over time. The long-term evidence data show patterns related to nerve impairment scores in the observed populations, but long-term effects are not fully established regarding the disease itself.


Evidence Level and Research Consistency

The evidence derived from settings with varying symptom burdens indicates that research exploring short-term symptom changes following intravenous administration data show patterns related to evidence consistency across multiple studies and meta-analyses. The evidence level for this specific, short-term context was observed in some studies to be classified as High.

For the intermediate-term use of oral administration, particularly when studying symptom change over several months, the evidence quality varies across studies, and findings were mixed. For this context, the evidence level was observed in some studies to be Moderate. For the long-term observation of nerve impairment scores over four years, data are still limited and the certainty remains low regarding any long-term effects on the underlying neuropathy progression.

Key Studies & References

  1. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial

Frequently Asked Questions (FAQ)

Common questions about Thiogamma (FAQ)

Q: Is Thiogamma a vitamin or a prescription drug?

A: Thiogamma contains the active ingredient thioctic acid (alpha-lipoic acid). This substance is scientifically classified as both a metabolic agent and an endogenous antioxidant, and it is considered a vitamin-like substance because it is vital for cell function.

The official product status as a prescription drug or an over-the-counter medicine can vary depending on the regulatory rules in a specific country.

Q: Is it normal to feel a metallic taste after a Thiogamma infusion?

A: A change in the sense of taste (dysgeusia) is listed as a documented, though very rare, adverse reaction in the official product information.

While the specific description of a 'metallic' taste is a common way patients report this sensation, the official labeling notes a general change in taste, particularly following an intravenous infusion.

Q: Does Thiogamma need to be taken with food, or on an empty stomach?

A: According to the official product information, the oral tablets must be taken on an empty stomach. This is typically done before the first meal of the day, as instructed in the product information.

Taking the tablets with food may interfere with the proper absorption and reduce the availability of the active substance.

Q: Can elderly patients safely take Thiogamma?

A: The official labeling does not include a specific age-based exclusion for the elderly population, in contrast to the explicit exclusion of children and adolescents.

Use in adults, including the elderly, is subject to the general contraindications and warnings, such as the need for blood sugar monitoring in diabetic patients.

Q: Is Thiogamma available over-the-counter in some countries?

A: The regulatory status of Thiogamma (alpha-lipoic acid) can differ significantly worldwide. It is regulated as a prescription drug in some regions while being available over-the-counter in others, often requiring consultation with a pharmacist.

Q: What are the signs that Thiogamma is starting to work for nerve pain?

A: Clinical trials for the active ingredient track changes in patient-reported sensory symptoms associated with polyneuropathy.

Studies monitored outcomes such as a reported reduction in the intensity and variability of challenging sensations like pain, burning, numbness, and tingling. These changes indicate the type of outcomes monitored by researchers.

Q: Are there specific foods or supplements to avoid while on Thiogamma?

A: According to official regulatory warnings, medicines and supplements containing metal compounds, such as those with iron or magnesium, must not be taken at the same time as Thiogamma.

These supplements can bind to the active substance, which may reduce the drug’s absorption and overall effectiveness. A sufficient time interval must be maintained between taking the two.

Q: What research studies support the use of Thiogamma for diabetic neuropathy?

A: The primary clinical evidence supporting the medication’s use for diabetic polyneuropathy is based on a series of Randomized Controlled Trials (RCTs).

These include the ALADIN and SYDNEY trials, which evaluated the effect of the active substance on patient-reported symptoms, particularly the short-term outcomes.

Q: What is the shelf life of Thiogamma tablets?

A: The official shelf life (expiry date) for Thiogamma is printed on the medication's original container by the manufacturer.

The product's regulatory requirements mandate that it should not be used after the expiry date shown on the packaging.

Q: Can taking too much Thiogamma cause an upset stomach?

A: Gastrointestinal issues like nausea, vomiting, and stomach pain are documented as very rare adverse reactions at the recommended dose.

However, official warnings highlight that an overdose is a serious medical event that requires immediate attention.

Q: Why do some people take Thiogamma as an antioxidant supplement?

A: The active substance in Thiogamma is classified as a potent endogenous antioxidant because it is capable of fighting damaging processes in the body.

It works by scavenging reactive oxygen species (ROS) and aiding in the regeneration of other natural antioxidants like glutathione. This capability is the fundamental basis for its therapeutic and supplemental use.

Q: Is it necessary to store Thiogamma in the refrigerator?

A: No, Thiogamma is not required to be stored in the refrigerator. The infusion solution must be stored at temperatures not exceeding 30 C and should be protected from light.

Film-coated tablets must be stored in their original package and kept away from moisture.

Q: Is Thiogamma considered a neuroprotective agent?

A: Regulatory documents classify the active substance as a metabolic agent and an endogenous antioxidant.

Its documented mechanism of action—supporting nerve cell energy supply and reducing oxidative damage—is generally described in the scientific context as providing a form of neuroprotective support to nerve tissue.

Q: Do you need to adjust your diet significantly while taking Thiogamma?

A: No significant changes to the overall diet are mandated by the regulatory documents. The most important requirement is to take the tablets on an empty stomach to ensure proper absorption.

If you take supplements containing iron or magnesium, you must adjust the timing of their intake to be separate from when you take Thiogamma.

Q: Can Thiogamma be crushed or split if the tablet is too large?

A: The official administration instructions require that the oral film-coated tablets must be swallowed whole with sufficient fluid. They are not intended to be crushed or split.

Q: Is there a risk of allergic reaction to Thiogamma?

A: Yes, there is a risk. Known hypersensitivity or allergy to the active substance or any component is an absolute contraindication.

Allergic reactions, ranging from simple skin rashes to, in rare cases, severe systemic reactions like anaphylactic shock, are documented adverse effects.

Q: How can I tell if a side effect is serious or just a common reaction to Thiogamma?

A: Official labeling highlights that symptoms such as difficulty breathing, severe allergic reactions (e.g., anaphylactic shock), and symptoms indicative of severe metabolic disturbances (like low blood sugar) require prompt medical attention.

These are typically listed as serious or very rare events, distinguishing them from common, transient effects.

Q: Does Thiogamma work on all types of nerve pain or just tingling/numbness?

A: The therapeutic indication for the medication is the symptomatic relief of diabetic polyneuropathy.

Clinical trials evaluate the effect on a range of nerve-related discomfort using the Total Symptom Score (TSS), which monitors changes in manifestations like lancinating pain, numbness, and tingling.

Q: Can Thiogamma be used by people who are lactose intolerant?

A: The film-coated tablets contain lactose monohydrate as an inactive ingredient (excipient).

Regulatory warnings state that the tablets are contraindicated for individuals with rare hereditary problems, such as total lactase deficiency or glucose-galactose malabsorption, due to the inclusion of lactose monohydrate.

How should Thiogamma be stored and disposed of?

The storage and disposal requirements for Thiogamma are documented by regulatory bodies, with specific rules for the infusion solution due to the photosensitivity of the active ingredient, Thioctic acid.

Official Storage Requirements

Product Form Mandatory Conditions
Infusion Solution Must be protected from light and stored in the original package until use. The infusion must be started immediately once the vial is opened, and the accompanying light-protection bag must be used during administration. Store at temperatures not exceeding 30 C.
Film-Coated Tablets Must be stored in the original package and kept away from moisture.

All forms must be stored out of the sight and reach of children.

Official Disposal Rules

Any unused or expired Thiogamma must be disposed of in accordance with local requirements. The product must not be disposed of via wastewater or household waste to prevent environmental contamination, following pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thiogamma found in:

A-Z Index: